Clusterin facilitates apoptotic cell clearance and prevents apoptotic cell-induced autoimmune responses by Cunin, P et al.
University of Wollongong
Research Online
Faculty of Science, Medicine and Health - Papers Faculty of Science, Medicine and Health
2016
Clusterin facilitates apoptotic cell clearance and












See next page for additional authors
Research Online is the open access institutional repository for the University of Wollongong. For further information contact the UOW Library:
research-pubs@uow.edu.au
Publication Details
Cunin, P., Beauvillain, C., Miot, C., Augusto, J., Preisser, L., Blanchard, S., Pignon, P., Scotet, M., Garo, E., Fremaux, I., Chevailler, A.,
Subra, J., Blanco, P., Wilson, M. R., Jeannin, P. & Delneste, Y. (2016). Clusterin facilitates apoptotic cell clearance and prevents
apoptotic cell-induced autoimmune responses. Cell Death and Disease, 7 e2215-1-e2215-11.
Clusterin facilitates apoptotic cell clearance and prevents apoptotic cell-
induced autoimmune responses
Abstract
Clusterin (Clu), an extracellular chaperone, exhibits characteristics of soluble innate immunity receptors, as
assessed by its ability to bind some bacteria strains. In this study, we report that Clu also binds specifically to
late apoptotic cells but not to live, early apoptotic, or necrotic cells. Histones, which accumulate on blebs
during the apoptotic process, represent privileged Clu-binding motifs at the surface of late apoptotic cells. As
a consequence, Clu potentiates, both in vitro and in vivo, the phagocytosis of late apoptotic cells by
macrophages. Moreover, the increased phagocytosis of late apoptotic cells induced by Clu favors the
presentation and cross-presentation of apoptotic cell-associated antigens. Finally, we observed that, in a model
of apoptotic cell-induced autoimmunity, and relative to control mice, Clu-/- mice develop symptoms of
autoimmunity, including the generation of anti-dsDNA antibodies, deposition of immunoglobulins and
complement components within kidneys, and splenomegaly. These results identify Clu as a new molecule
partner involved in apoptotic cell efferocytosis and suggest a protective role for Clu in inflammation and
autoimmune diseases.
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Clusterin facilitates apoptotic cell clearance and
prevents apoptotic cell-induced autoimmune
responses
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Clusterin (Clu), an extracellular chaperone, exhibits characteristics of soluble innate immunity receptors, as assessed by its ability
to bind some bacteria strains. In this study, we report that Clu also binds specifically to late apoptotic cells but not to live, early
apoptotic, or necrotic cells. Histones, which accumulate on blebs during the apoptotic process, represent privileged Clu-binding
motifs at the surface of late apoptotic cells. As a consequence, Clu potentiates, both in vitro and in vivo, the phagocytosis of late
apoptotic cells by macrophages. Moreover, the increased phagocytosis of late apoptotic cells induced by Clu favors the
presentation and cross-presentation of apoptotic cell-associated antigens. Finally, we observed that, in a model of apoptotic cell-
induced autoimmunity, and relative to control mice, Clu− /− mice develop symptoms of autoimmunity, including the generation of
anti-dsDNA antibodies, deposition of immunoglobulins and complement components within kidneys, and splenomegaly. These
results identify Clu as a new molecule partner involved in apoptotic cell efferocytosis and suggest a protective role for Clu in
inflammation and autoimmune diseases.
Cell Death and Disease (2016) 7, e2215; doi:10.1038/cddis.2016.113; published online 5 May 2016
Clusterin (Clu), also known as apolipoprotein J, is a soluble
80-kDa disulfide-linked heterodimeric glycoprotein which is
highly conserved during evolution and among mammals.1 Clu
is abundant in physiological fluids (concentrations ranging
from 100 to 300 μg/ml in human serum)2–4 and is induced in
response to a wide variety of tissue injuries. Clu has
chaperone activity and is a functional homolog to small heat-
shock proteins.5,6 It binds hydrophobic domains of numerous
non-native proteins and targets them for receptor-mediated
internalization and lysosomal degradation. Clu also interacts
with a broad spectrum of molecules (such as lipids,
components of the complement system, amyloid-forming
proteins, immunoglobulins)7,8 and has been suggested to
regulate several functions, such as complement activity, cell–
cell and cell–substratum interactions, and cell proliferation/
survival.1 In various diseases, an accumulation of Clu has
been reported in the injured organs.9,10
Clu also interacts with different immune molecules; how-
ever, its potential role in immune responses remains unclear.
Clu binds to some bacteria (Staphylococcus aureus and some
Staphylococcus epidermidis strains) and bacterial proteins
(such as the Streptococcus pyogenes extracellular protein
SIC),11–13 suggesting that it may modulate antimicrobial
responses. Moreover, Clu limits the severity of induced
autoimmune myocarditis14 and pancreatitis.15 Finally, the
levels of circulating Clu in systemic lupus erythematosus,16
as well as the expression of Clu mRNA in the synovium of
rheumatoid arthritis patients, are decreased.17
Phagocytosis of dying cells, a process called efferocytosis,
is a complex mechanism that involves (i) exposure at the
apoptotic cell surface of phosphatidylserine (PS) and mem-
brane molecules that are altered during the apoptotic
process,18 and (ii) endocytic receptors expressed by phago-
cytes, such as members of the scavenger receptor family,19
vitronectin receptors,20 Fc receptors,21 MER,22 TIM-1 and
TIM-4,23 and CD91.24 Soluble receptors (also called opso-
nins), such as C1q, mannose-binding lectin (MBL),25 and milk
fat globule-EGF factor 8 (MFG-E8),26 bind to apoptotic cells
and act as bridging molecules to favor their internalization by
phagocytes. In a non-inflammatory environment, a rapid
and efficient clearance of apoptotic cells maintains immune
homeostasis and avoids the initiation of autoimmune
responses.27,28 In contrast, a dysfunction in the clearance of
apoptotic cells may result in the release of danger molecules
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(referred to as danger-associated molecular patterns) that
may favor the initiation of autoimmune responses.27,28
The pivotal role played by soluble molecules in apoptotic
cell clearance and, consequently the outcome of immune
responses to apoptotic cell antigens, has been clearly
evidenced in opsonin-deficient mice. For example, mice
deficient in MFG-E8, C1q, or serum amyloid P component
(SAP) show impaired clearance of apoptotic cells and develop
a lupus-like disease characterized by elevated levels of
autoantibodies and glomerulonephritis.29–31
Some soluble innate immunity receptors involved in micro-
bial recognition have also been implicated in apoptotic cell
clearance.19 As Clu binds to microbial moieties,9–11 we
investigated whether Clu might also mediate apoptotic cell
clearance by phagocytes.
Results
Clu binds to late apoptotic cells. We first evaluated the
ability of recombinant human Clu to bind to spontaneously
dying human neutrophils. As previously described,32 four
populations can be distinguished by flow cytometry, based
on annexin V (Ann V) and propidium iodide (PI) staining
(Figure 1a, left panel): viable (Ann V− PI−, corresponding to
R1), early apoptotic (Ann V+ PI−; R2), late apoptotic (Ann V+
PI+; R3), and secondary necrotic cells (Ann V+/− PIhigh; R4).
Results showed that Oregon Green 488 (OG)-labeled Clu
(OG-Clu) binds to late apoptotic (R3) and, to a low extent, to
secondary necrotic neutrophils (R4), but not to viable (R1)
and early apoptotic (R2) neutrophils (Figure 1a, middle
panels). A low binding of OG-Clu was also detected to
heat-induced necrotic neutrophils (Figure 1a, right panel).
Similar binding profiles were obtained using purified and
recombinant Clu revealed by a FITC-labeled anti-Clu mAb
(Figure 1b). As control,25,33 OG-C1q binds preferentially to
late apoptotic and secondary necrotic cells (Figure 1b). No
binding of the control protein OG-HSA (human serum
albumin) was observed on dying cells (Figure 1b).
We next investigated whether Clu present in human serum
also binds to late apoptotic cells. Dying neutrophils were
incubated with human serum and bound Clu was detected
using a FITC-labeled anti-Clu mAb. Results showed that Clu
present in human serum binds to late apoptotic cells and that
the level of binding was dependent on the concentration of
serum used (Figure 1c); no binding of the anti-Clu mAb on
late apoptotic cells was observed in the absence of serum
(Figure 1c), demonstrating that intracellular Clu does not
translocate to the surface of dying cells during the apoptotic
process. Finally, we observed that Clu also binds to (i) late
apoptotic Jurkat cells (induced by etoposide or an anti-Fas
mAb) (Figure 1d), (ii) apoptotic murine thymocytes
(Supplementary Figure S1A), and (iii) tumor cells either
irradiated or treated with etoposide (Supplementary
Figure S1B), demonstrating that the binding of Clu to late
apoptotic cells is not dependent on the cell type or on the
apoptosis-inducing signal.
Clu binds to histones expressed at the surface of late
apoptotic cells. The binding of OG-Clu to late apoptotic
neutrophils is dose dependent, partly saturable (Figure 2a),
and is inhibited in a dose-dependent manner, by unlabeled
Clu, but not by HSA (Figure 2b). Fluorescence microscopy
revealed an intense staining on bleb-like structures (Figure 2c).
Figure 1 Clu binds to late apoptotic cells. (a) Left panel, analysis of spontaneous apoptosis of human neutrophils after culture in 1% FCS culture medium and staining with PI
and APC-labeled Ann V. Flow cytometry analysis allowed to identify four populations corresponding to viable (Ann V− PI−; R1), early apoptotic (Ann V+ PI−; R2), late apoptotic
(Ann V+ PI+; R3), and necrotic cells (Ann V+/− PIhigh; R4), respectively. Middle panels, dying neutrophils were incubated or not with 1 μM OG-Clu; the binding of Clu to R1–R4
populations was evaluated by flow cytometry. Right panel, binding of OG-Clu to heat-induced necrotic neutrophils. Results are representative of five independent experiments.
(b) Neutrophils, at different apoptosis stages (R1–R4), were incubated with 1 μM OG-HSA, OG-Clu, OG-rClu, or OG-C1q. Binding was analyzed by flow cytometry. Results are
expressed in MFI values, mean± S.E.M., n= 5. (c) Late apoptotic neutrophils were incubated with increasing concentration of human serum and stained with an anti-Clu or
isotype-matched mAb. Bound Abs were detected by flow cytometry using a FITC-labeled anti-mouse Ig Ab. Results are expressed in MFI values, mean± S.E.M., n= 4.
(d) Binding of OG-Clu to late apoptotic Jurkat T cells. The apoptosis was induced with 20 μg/ml etoposide or 20 ng/ml anti-FAS mAb. Results are expressed in MFI values,
mean± S.E.M., n= 4
Clusterin favors apoptotic cell clearance
P Cunin et al
2
Cell Death and Disease
This binding was reduced on apoptotic neutrophils (Figure 2d),
which were left to die in the presence of Y-27632, an inhibitor
of membrane blebbing.34 These observations suggested
the presence of Clu-binding elements at the surface of late
apoptotic cells.
The apoptotic process is accompanied by cell surface
alterations, such as PS externalization, membrane relocaliza-
tion of intracellular components, and oxidation of membrane
molecules;35,36 these motifs act as 'eat-me' molecules. In an
attempt to characterize the nature of the Clu-binding motif(s),
we evaluated whether a treatment with DNase, glycosidases,
or pronase may modulate the binding of Clu to late apoptotic
cells. DNase strongly upregulated the binding of Clu to
apoptotic Jurkat cells (increase of 362±51%; mean±S.E.M.,
n= 4; Figures 3a and b); as a control for DNase efficiency, the
staining with PI and the binding of an anti-dsDNA mAb was
lower on DNase-treated than on non-treated apoptotic cells
(Figures 3a and b). In contrast, pronase or glycosidases did
not modulate the binding of Clu to apoptotic cells (Figure 3b);
as enzyme controls, pronase and glycosidases decreased the
binding on late apoptotic cells of anti-CD45RA mAb37 and of
the lectin wheat germ agglutinin (WGA),38 respectively
(Figure 3b). The treatment of late apoptotic cells with DNAse
and pronase strongly accelerated the generation of remnant
cells (data not shown), excluding evaluating the binding of Clu
on apoptotic cells treated with the two enzymes. Finally, a
negligible amount of Clu bound to erythrocytes treated with
ionomycin (Supplementary Figure S2A), which induces
phospholipid externalization,39 making unlikely a role for
externalized lipids in the binding of Clu. Accordingly, no
binding of Clu was detected on immobilized lipids (Supple-
mentary Figure S2B).
The fact that DNAse increased the binding of Clu to late
apoptotic cells suggested that DNA may sterically mask Clu-
binding elements. As genomicDNA is associatedwith histones,
we suspected that histones might represent Clu-binding
elements. A solid-phase binding assay showed that Clu binds
to immobilized H2A, H2B, H3, and H4, and, to a lower extent, to
the linker subunit H1 (Figure 3c). As control,40,41 C-reactive
protein (CRP) and SAP, but not HSA, also bind to histones
(Figure 3c). No binding of Clu to immobilized dsDNA was
observed (Figure 3c); as a control, immobilized dsDNA was
recognized by anti-dsDNA Abs (data not shown).
We then confirmed that histones, translocated to the surface
of apoptotic cells, represent Clu-binding elements. As
reported,36 histones can be detected at the surface of late
apoptotic neutrophils but not on viable, early apoptotic, and
necrotic neutrophils (Figure 3d). Interestingly, DNAse increased
the binding of an anti-histone Ab (Supplementary Figure S2C),
confirming that DNA may mask Clu-binding motifs on histones
at the surface of late apoptotic cells. Finally, confocal micro-
scopy revealed a partial colocalization between OG-Clu and
histones at the surface of apoptotic cells (Figure 3e).
Clu is involved in the clearance of apoptotic cells.
Opsonins act as bridging molecules to favor apoptotic cell
clearance. We therefore examined whether Clu may be
involved in apoptotic cell clearance using a FACS-based
Figure 2 Clu-binding elements are localized on blebs. (a) Late apoptotic neutrophils were incubated with increasing concentrations of OG-Clu or OG-HSA; the binding was
analyzed by flow cytometry. Results are expressed in MFI values, mean± S.E.M., n= 5. (b) Late apoptotic neutrophils were incubated with the indicated concentrations of
unlabeled Clu or HSA before addition of 1 μM OG-Clu; the binding of OG-Clu was analyzed by flow cytometry. Results are expressed as the percentages of inhibition, mean±
S.E.M., n= 5. (c) Differential interference contrast (DIC; left panel) and confocal fluorescence (right panel) microscopic images of late apoptotic neutrophils incubated with OG-
Clu. Images are representative of two independent experiments. White arrows, blebs; original magnification, × 630. (d) Neutrophils were incubated or not with 50 μg/ml Y-27632,
prior to apoptosis induction. The binding of OG-Clu was evaluated by flow cytometry. Histograms are representative of three independent experiments
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in vitro apoptotic cell engulfment assay.42,43 Macrophages
(Mφ) were fed with PKH67-labeled early or late apoptotic
neutrophils, previously incubated or not with Clu, MBL, or
HSA. Compared with the control protein HSA, Clu enhanced
the phagocytosis of apoptotic cells (69±12% increase;
mean±S.E.M., n=6) in a similar manner to MBL (67± 14%
increase) (Figure 4a) used as a positive control.25 In
agreement with the absence of binding to early apoptotic
cells, Clu did not modulate the efferocytosis of AnnV+ PI−
cells (Figure 4a). In order to investigate the role of seric Clu,
late apoptotic neutrophils were incubated with heat-
inactivated human serum, either depleted or not in Clu.
Depletion of Clu reduced the phagocytosis of apoptotic cells
(26±6% decrease; mean±S.E.M., n=5); this inhibition was
partially reversed by supplementing Clu-depleted serum with
exogenous Clu (Figure 4b).
Prior to analyzing the role of Clu in the in vivo clearance of
apoptotic cells, we confirmed the ability of Clu to promote the
in vitro phagocytosis of apoptotic murine cells. Results
showed that (i) late apoptotic thymocytes opsonized with Clu
are more efficiently internalized by Mφ than apoptotic cells
incubated with HSA (46±7% increase; mean±S.E.M., n=5;
Figure 4c), and (ii) that apoptotic thymocytes incubated with
serum from Clu− /− mice were less efficiently engulfed by Mφ
than apoptotic cells incubated with serum from wild-type (WT)
mice (12±2% decrease; mean±S.E.M., n= 6; Figure 4d).
The in vivo role of Clu in apoptotic cell clearance was
investigated using Clu− /− mice. In a first set of experiments,
we compared, in WTand Clu− /− mice, the clearance of dying
thymocytes in which apoptosis was induced by dexametha-
sone sodium phosphate (Dex).22,44 Remarkably, the thymus of
Dex-injected Clu− /− mice contained approximately twofold
more remnant apoptotic cells than Dex-injected WT mice
(15±3% versus 8± 2%; mean±S.E.M., n=5; Figure 4e); we
excluded that this observation may result from an increased
sensitivity of thymocytes from Clu− /− mice to Dex-induced
apoptosis (Supplementary Figure S3A). In contrast, no
difference was observed in Clu− /− and WT mice injected with
PBS (Figure 4e). In a second set of experiments, we analyzed
the splenic clearance of PKH67-labeled apoptotic thymocytes
injected intravenously in Clu− /− and WT mice. Two hours
after injection, the spleens from Clu− /− mice contained
more apoptotic cells than WT mice (0.56±0.06% versus
0.44±0.03%; mean±S.E.M., n=4; Figure 4f); this defect was
maintained 6 h after apoptotic cell injection (data not shown).
Importantly, Mφ from Clu− /− mice do not exhibit any defect in
apoptotic cell phagocytosis (Supplementary Figure S3B).
Clu enhances CD4+ and CD8+ T-cell responses to an
apoptotic cell-associated antigen. The engulfment of
apoptotic cells by phagocytes leads to the presentation of
Figure 3 Clu binds to histones expressed on late apoptotic cells. (a) Late
apoptotic Jurkat T cells were treated with 500 μg/ml DNase prior to incubation with
1 μM OG-Clu. DNase efficiency was assessed by PI staining. Dot plots are
representative of four independent experiments. (b) Binding of OG-Clu to apoptotic
Jurkat T cells treated with 500 μg/ml DNase, 100 μg/ml pronase, or 100 μg/ml
glycosidase. As controls of DNase, pronase, and glycosidase efficiency, binding of PI,
anti-dsDNA mAb, anti-CD45RA mAb, and FITC-labeled WGA was analyzed. Results
are expressed as a percentage of variation of the binding of Clu, PI, anti-dsDNA mAb,
anti-CD45RA mAb, and WGA on treated compared with non-treated cells, mean±
S.E.M., n= 4. (c) H1, H2A, H2B, H3, and H4 histone subunits and genomic human
DNA were immobilized on a 96-well plate. Binding of biotinylated-HSA, -Clu, -CRP,
and -SAP to histone subunits and DNA was determined by enzyme-linked
immunosorbent assay. Results are expressed in OD values, mean± S.E.M.; n= 5.
*Po0.05 compared to none (Mann-Whitney test). (d) Apoptotic neutrophils were
labeled with anti-H2/H3/H4 or isotype control mAbs, before incubation with a FITC-
labeled anti-mouse IgG Ab. Live (R1), early apoptotic (R2), late apoptotic (R3), and
necrotic neutrophils (R4) were discriminated by flow cytometry using Ann V and PI
staining. Results are representative of one out four experiments. (e) Apoptotic
neutrophils were incubated with OG-Clu in the presence of anti-H4 (upper panels) or
anti-H2/H3/H4 mAbs (lower panels) prior to incubation with a PE-labeled anti-mouse
IgG Ab. Presence of OG-Clu and histones on cell surface was assessed by confocal
microscopy. DNA was stained with DAPI. Original magnification, × 630. Images are
representative of one of the four experiments
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apoptotic cell-derived antigens, a process contributing to the
maintenance of peripheral tolerance.45–47 We therefore
analyzed whether Clu might promote apoptotic cell antigen
presentation to CD4+ and CD8+ T cells. Murine thymocytes
were loaded with ovalbumin (Ova) prior to apoptosis
induction (Ova-Apopt). In a first set of experiments, dendritic
cells (DCs) were incubated with Ova-Apopt previously
incubated with Clu or HSA, before culture with Ova-specific
OT1 CD8+ or OT2 CD4+ T cells. Results showed that the
opsonization of Ova-Ova-Apopt with Clu enhanced the
production of IL-2 by OT1 and OT2 T cells, compared with
Ova-Ova-Apopt incubated with HSA (200± 64% and
Figure 4 Clu increases apoptotic cells clearance in vitro and in vivo. (a) Mφ were fed for 30 min with PKH67-labeled early (upper panels) or late apoptotic neutrophils (lower
panels) (1 : 10 ratio) previously opsonized or not with 1 μM Clu, MBL, or HSA before incubation with APC-labeled anti-HLA DR mAb. Fluorescence was analyzed by flow
cytometry. Left, contour plots are representative of two (upper panels) or six (lower panels) independent experiments; values correspond to the percentage of Mφ having engulfed
dying cells. Right, results of phagocytosis assays using late apoptotic cells are expressed as a phagocytic index (see Materials and Methods); individual determinations are
plotted, means are represented by horizontal bars. *P≤ 0.05. (b) Mφ were fed with PKH67-labeled late apoptotic neutrophils previously incubated in the presence of 30% (v:v)
human AB+ serum, depleted or not in Clu, and supplemented or not with 1 μMClu. Results are shown as a phagocytic index, mean± S.E.M.; n= 4. *P≤ 0.05; NS, not significant.
(c) BMDM were fed with PKH67-labeled late apoptotic murine thymocytes (1 : 5 ratio) previously opsonized with 1 μM Clu or HSA before incubation with PE-labeled anti-F4/80
mAb. Fluorescence was analyzed by flow cytometry. (d) PKH67-labeled late apoptotic thymocytes were incubated with 1% serum from WTor Clu− /− mice. The phagocytosis
assay was performed as previously described. (e) Clu− /− and WT mice (n= 5) were injected intraperitoneally with Dex or with PBS. After 24 h, the frequency of Ann V+ apoptotic
cells in the thymus was determined by flow cytometry. Left, representative histograms are shown. Values correspond to the percentage of apoptotic cells. Right, results are
expressed as the percentage of apoptotic cells, mean± S.E.M., n= 4; *P≤ 0.05. (f) PKH67-labeled late apoptotic thymocytes (1 × 108) or PBS were injected intravenously in WT
and Clu− /−mice. The frequency of PKH67-positive events within splenocytes 2 h after injection was evaluated by flow cytometry. Left, representative dot plots are shown. Values
correspond to the percentage of PKH67-positive cells. Right, results are shown as the percentage of the PKH67-positive cells, mean± S.E.M., n= 4; *P≤ 0.05
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121±19% increase, respectively; mean±S.E.M., n=6;
Figure 5a). In a second set of experiments, DCs were
incubated with Ova-Ova-Apopt previously incubated with
10% serum from Clu− /− or WT mice before culture with Ova-
specific T cells. The levels of IL-2 produced by OT1 and OT2
T cells were lower with Ova-Ova-Apopt incubated with
serum from Clu− /− mice versus serum from WT mice
(32±8% and 34±9% decrease, respectively; mean±S.E.M.,
n= 4; Figure 5b).
Clu-deficient mice are sensitive to apoptotic cell-induced
autoimmunity. A defect in apoptotic cell clearance may
trigger an autoimmune response.27,44,48 We thereby postu-
lated that the absence of Clu might predispose mice to
apoptotic cell-induced autoimmunity. We compared, in Clu− /−
and WT mice, the appearance of signs of autoimmunity in a
model of mild autoimmune response induced by repeated
injections of apoptotic cells.47,49 Results showed that,
2 weeks after the first injection of apoptotic cells, the levels
of IgG anti-dsDNA Ab were increased in Clu− /−
mice compared with WT mice (2638 U/ml±282 versus
1823 U/ml±450, respectively; Figure 6a). In contrast to WT
mice, which only developed a slight and transient upregula-
tion 6 weeks after the first injection of apoptotic cells, the
levels of IgG anti-dsDNA Abs were significantly higher and
maintained elevated in Clu− /− mice, 10 weeks after the first
injection of apoptotic cells (Figure 6a). The basal levels of
anti-dsDNA Abs remained stable in non-injected Clu− /− mice
and were equivalent to the ones in WT mice, although a slight
increase was observed as the animal aged (Figure 6a).
Interestingly, no difference in the kinetics and amplitude of
IgG anti-Ova Ab titers was observed between Clu− /− and WT
mice immunized with Ova (Supplementary Figure S4A),
suggesting that the induction of anti-dsDNA Abs in Clu− /−
mice did not result from an abnormal capacity to mount a
humoral response. Interestingly, glomerular IgG and comple-
ment component C4 deposits were observed in Clu− /− but
not in WT mice, 10 weeks after injection of apoptotic cells
(Figure 6b); no deposit was observed in Clu− /− and WT mice
injected with PBS (Supplementary Figure S4B). Upon
injection of apoptotic cells, the spleen weight of Clu− /− mice
was slightly but significantly increased, compared with WT
mice (increase of 38±10%; mean±SEM, n= 4), 8 weeks
after the first injection of apoptotic cells (Figure 6c). Moreover,
10 weeks after the first injection of apoptotic cells, relative to
WT mice, the liver expression of SAP mRNA was enhanced
in Clu− /− mice (Figure 6d).
The generation of class-switched IgG autoantibodies in
Clu− /− mice suggested the role of T cells. We first analyzed
the frequency of naive (CD44− CD62Lhigh), central memory
(CD44+ CD62Lhigh), and effector memory (CD44+
CD62Llow)50 CD4+ and CD8+ T cells. Results showed an
increase in the frequency of CD44+ CD62Llow cells within both
CD4+ and CD8+ T-cell subsets, 10 weeks after the first
injection of apoptotic cells (Figure 7a). Moreover, the ratio of
CD44+ CD62Llow and CD44+ CD62Lhigh cells among CD4+
and CD8+ T cells were significantly increased in the lymph
nodes of Clu− /− (1.10±0.07 and 0.28±0.07, respectively;
mean±S.E.M., n= 5) compared with WT mice (0.70±0.14
and 0.14± 0.03, respectively) (Figure 7b). The total
numbers of CD4+ and CD8+ T cells, B cells, Mφ, and DCs
(Supplementary Figure S5A), as well as the frequency of
regulatory, memory, naive, and activated T cells, and of
activated B cells (Supplementary Figure S5B), were equiva-
lent in the lymph nodes and spleens of non-treated 12-week-
old WT and Clu− /− mice. We next determined whether the
increased percentage of CD44+ CD62Llow CD8+ and CD4+
T cells in apoptotic cell-injected Clu− /− mice had functional
implications. Upon stimulation with phorbol myristic acetate
(PMA) plus ionomycin, lymph node CD8+ and CD4+ T cells
from Clu− /− mice produced significantly more IL-2 than cells
fromWTmice (Figure 7c), while only CD8+ T cells from Clu− /−
mice produced significantly more IFN-γ than cells from WT
mice (Figure 7d).
Discussion
Even though suspected, the potential role of Clu in immune
homeostasis remains largely unexplored. We report here that
Clu promotes the clearance of late apoptotic cells via its
unique capacity to bind to histones translocated to the
surface of apoptotic cells. Accordingly, Clu− /− mice develop
signs of autoimmunity in a model of apoptotic cell-induced
autoimmunity. These results identify Clu as a new bridging
Figure 5 Clu enhances the presentation of apoptotic cell-associated antigen. Thymocytes from Swiss mice were pulsed or not with 35 μM Ova and induced to die by serum
deprivation. Apoptotic thymocytes pulsed with Ova (Ova-Apopt) or not (Apopt) were incubated for 30 min (a) with Clu or albumin or (b) with 10% serum from WTor Clu− /− mice
before culture with BMDCs and OT1 or OT2 cells. IL-2 was quantified in the 24-h supernatants by enzyme-linked immunosorbent assay. Results are expressed in pg/ml,
mean± S.E.M.; n= 6; *P≤ 0.05
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molecule involved in the maintenance of tolerance to self-
antigens.
After apoptotic cell engulfment, professional antigen-
presenting cells (APCs) activate tolerogenic pathways that
prevent local inflammatory reactions.44,48 They produce
immunoregulatory cytokines (TGFβ, IL-10) and low or no
proinflammatory cytokines and chemokines.51 In this
immunoregulatory environment, the presentation and cross-
presentation of apoptotic cell antigens by APCs maintain
peripheral T-cell tolerance.47,52 In contrast, in the absence of
prompt clearance, apoptotic cells may evolve into immunolo-
gically harmful secondary necrotic cells which release danger
signals that may favor the initiation of an autoimmune
response.27,53 Necrotic cells also trigger the production of
inflammatory mediators by APCs.54 A rapid and efficient
efferocytosis is thus required to maintain immune tolerance.
In this study, we demonstrate that Clu, via its unique property
to potentiate efferocytosis, prevents the in vivo generation
of necrotic cells and thereby contributes to maintain self-
tolerance.
Despite the loss of billions of cells each day, the incidence of
histologically detectable apoptotic cells is rare in normal
tissues because of the efficiency of efferocytosis.22,44 We
showed that Clu binds specifically to late apoptotic cells,
suggesting that, under normal physiological conditions, Clu
will have only a minor role in apoptotic cell clearance.
Accordingly, Clu− /− mice do not exhibit spontaneous signs
of autoimmunity, as observed for most opsonin-deficient mice.
Aged MBL-deficient mice do not develop autoimmunity even
on a lupus-prone genetic background 129×C57BL/6.55 More-
over, SAP− /− and C1q− /− mice only develop autoimmunity on
the mixed 129×C57BL/6 or MRL/Mp background.30,31 To our
knowledge, MFG-E8− /− mice are the only opsonin-deficient
model that spontaneously develop an autoimmune phenotype
with aging.29
The role of Clu in efferocytosis suggests the existence of
endocytic receptor(s) for Clu. Megalin was described as a
receptor for Clu involved in the uptake of Clu-associated
misfolded proteins at the cerebral vascular endothelium and
choroid epithelium56 and in the endocytosis of cellular debris
by epithelial cells.57 In humans, however, the expression of
megalin is restricted to the proximal tubule of the kidneys, the
choroid plexus epithelium, and ependymal cells lining the
brain ventricules,58 making it unlikely to represent a major
endocytic receptor for Clu-mediated efferocytosis by phago-
cytes. Accordingly, we failed to detect megalin by human
Mφ (unpublished observations). Recent studies have reported
that Clu binds to some scavenger receptors5 and DC-SIGN,59
suggesting that these endocytic receptors may be involved in
the internalization of Clu-opsonized apoptotic cells. Experi-
ments are in progress to identify Clu-binding elements
involved in the capture of late apoptotic cells by phagocytes.
We have observed that Clu binds specifically to blebs on
late apoptotic cells, as reported for other opsonins, such as
CRP and SAP.60 The fact that the binding of Clu is not
dependent on the cell type nor on the apoptosis-inducing
method suggested that the Clu-binding motifs are conserved
molecules. We demonstrate here that Clu binds to histones.
Previous studies have shown that core histone subunits
rapidly accumulate in the cytoplasm of early apoptotic
cells61,62 before accumulation on blebs.36,63 Accordingly, we
observed that histones are expressed by late but not early
apoptotic cells, explaining the lack of binding of Clu to early
apoptotic cells. These results confirm the role of histones as
'eat-me' molecules at the surface of late apoptotic cells.
Defects in apoptotic cell clearance and/or an excess of
apoptotic cells make mice and humans susceptible to
autoimmunity.28 Although efferocytosis ismediated bymultiple
and partly redundant mechanisms to avoid the initiation of an
Figure 6 Clu-deficient mice develop autoimmune symptoms in response to
apoptotic cells. Aged-matched Clu− /− and WT mice were injected with apoptotic
cells once a week for 5 weeks. Two weeks after the first injection of apoptotic cells,
4–6 mice per group were killed bimonthly. (a) Circulating IgG anti-dsDNA antibody
levels were quantified. Results are expressed in kU/ml, mean±S.E.M., n= 4 to 10;
*P≤ 0.05. Insert, IgG anti-dsDNA antibody titers were quantified by enzyme-linked
immunosorbent assay in the serum of PBS-injected Clu− /− and WT mice. (b) Ten
weeks after the first injection of apoptotic cells, kidney sections from Clu− /− and WT
mice were stained with FITC-labeled anti-mouse IgG (left pictures) or unlabeled anti-
C4 revealed with a FITC-labeled anti-rat IgG antibodies (right pictures). Glomeruli
were stained with DAPI (circles). Results are representative of four mice. (c) Spleens
of WTand Clu− /− mice were weighed 10 weeks after the first injection of apoptotic
cells or PBS. Results are expressed in mg, mean± S.E.M., n= 4; *P≤ 0.05. (d) The
expression of the mRNA encoding SAP was analyzed by quantitative PCR in the
livers from Clu− /− and WT mice 10 weeks after the first injection of apoptotic cells or
PBS. Results are expressed as a relative expression with GAPDH used as a
calibrator, mean;± S.E.M., n= 5; *Po0.05
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autoimmune response, it has been reported that repeated
injections of apoptotic cells may induce signs of autoimmunity
(without clinical signs).49 Considering the role of Clu in
efferocytosis, we hypothesized that an excess of apoptotic
cells could be less efficiently cleared in Clu− /−mice, leading to
a more intense immune response. Indeed, we observed that
Clu− /− mice are more sensitive to apoptotic cell-induced
autoimmunity. They develop signs of autoimmunity, such as
immunoglobulin and complement component C4 deposition
within kidneys, autoantibody production, and splenomegaly.
In parallel, we observed an activation of effector memory
apoptotic cell antigen-specific T cells in Clu− /− mice. In line
with these results, previous studies reported that, in models of
autoimmune pancreatitis and myocarditis, Clu− /− mice
develop more severe inflammatory lesions than WT
mice.14,15 However, the mechanism(s) involved in this
protective role of Clu was not investigated. Considering our
results, it is likely that, in these models associated with a
massive cell death, the absence of Clu may have contributed
to initiate apoptotic cell-driven autoimmunity.
In conclusion, we show that Clu is a non-redundant opsonin
critically involved in the efferocytosis of late apoptotic cells
and the maintenance of immune homeostasis. In vivo, Clu
deficiency leads to a striking autoimmunity induced by the
injection of apoptotic cells, a model that mimics a massive
cell death that can occur during severe tissue injuries.
These results also suggest that Clu may have a protective
role against the establishment of chronic sterile inflammatory
disorders. This study opens new insights into how to
induce tolerance to self-antigens in autoimmune diseases
and to optimize immunogenic cell death in antitumor
immunotherapies.
Materials and Methods
Proteins and antibodies. Human Clu was purified from plasma, as
previously described.7 Recombinant human MBL and human and murine Clu were
from Biotechne (Lille, France). HSA, C1q, and FITC-labeled WGA were from Sigma-
Aldrich (St. Louis, MO, USA). SAP (Calbiochem, Darmstadt, Germany), CRP
(Millipore, Billerica, MA, USA), and H1, H2A, H2B, H3, and H4 histone subunits
(New England Biolabs, Ipswich, MA, USA) were from the indicated providers.
Proteins were labeled with Oregon green 488 dye (FluoReporter Oregon Green 488
Protein Labeling Kit; Invitrogen Molecular Probes, Carlsbad, CA, USA) or
biotinylated (EZ-Link Sulfo-NHS-LC-Biotin Kit; Pierce, Rockford, IL, USA) using
the commercial kits. The origins and clone numbers of the mAbs used in this study
are listed in Table 1.
Isolation and generation of human leukocytes. Blood from healthy
subjects was obtained from the Blood collection center of Angers (agreement ANG
2003-2). Human peripheral blood mononuclear cells (PBMCs) were isolated by
Figure 7 Memory T cells from apoptotic cell-injected Clu-deficient mice exhibit an activated phenotype. Clu− /− and WT mice were injected with apoptotic cells once a week
for 5 weeks. Two weeks after the first apoptotic cell injection, 4–6 mice per group were killed bimonthly. The phenotype and function of memory T cells was analyzed 10 weeks
after the first injection in Clu− /− and WT mice. (a) Lymph node cells were stained with PeCy5-labeled anti-CD3, APCeFluor 780-labeled anti-CD4 or -CD8, FITC-labeled anti-
CD62L, and PE-labeled anti-CD44 mAbs. Density plots represent cells gated on the CD3+ CD4+ (left) and CD3+ CD8+ (right) populations. Flow cytometric analysis identified
CD44− CD62Lhigh naive T cells, CD44+ CD62Lhigh central memory T cells, and CD44+ CD62Llow effector memory T cells. Values correspond to the percentage of each subset.
(b) CD62Llow/CD62Lhigh cell ratio among CD3+ CD4+ CD44+ (left histograms) and CD3+ CD8+ CD44+ (right histograms) cells in the lymph nodes of WT and Clu− /− mice.
(c and d) Lymph node cells from Clu− /− and WT mice were stimulated in vitro with PMA plus ionomycin in the presence of brefeldin A, before staining with PeCy5-labeled anti-
CD3, FITC-labeled anti-CD4, APCeFluor 780-labeled anti-CD8, PE-labeled anti-IL-2, and APC-labeled anti-IFNγ mAbs. Percentages of IL-2- (c) and IFNγ-secreting cells (d)
among CD3+ CD4+ (left histograms) and CD3+ CD8+ (right histograms) are shown. (b-d). Mean± S.E.M., n= 4 to 6; *P≤ 0.05
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Ficoll-Paque (Amersham Biosciences, Uppsala, Sweden) density-gradient centri-
fugation. To generate Mφ, monocytes were purified from PBMC by positive
selection using anti-CD14 mAb-coated magnetic beads (Miltenyi Biotech, Bergisch
Gladbach, Germany); purity was 499% (data not shown). Purified CD14+
monocytes (1 × 106 cells/ml) were differentiated into Mφ by 5-day culture with 20 ng/
ml M-CSF (Biotechne) and 2 ng/ml GM-CSF (CellGenix, Freiburg, Germany) in
complete medium (CM), consisting of RPMI 1640 medium containing 2 mM
L-glutamine, antibiotics (all from Lonza, Verviers, Belgium), and 10% (v/v) heat-
inactivated fetal calf serum (Biowest, Nuaillé, France). After Ficoll-Paque
centrifugation, neutrophils were isolated from erythrocytes by 1.5% (w/v) dextran
(Amersham Biosciences) density-gradient sedimentation. Contaminating red blood
cells were lysed by hypo-osmotic shock. Purity was routinely 498% (data not
shown).
Isolation and generation of murine leukocytes. C57BL/6 mice and
Ova-specific T-cell receptor transgenic mice OT1 and OT2 (C57BL/6 background)
were from Charles River Laboratories (L'Arbresle, France). Clu− /− mice (C57BL/6
background) were from The Jackson Laboratory (Bar Harbor, ME, USA). Mice were
bred and housed in a pathogen-free environment. Experiments were conducted
according to institutional guidelines and were approved by the institutional ethics
committee of Région des Pays de la Loire (agreement 2009.18).
Murine Mφ and DC generation: Non-myeloid bone marrow cells were
removed after incubation of total bone marrow cells with 10 μg/ml anti-CD4, -CD8,
-B220, and -I-Ab mAbs for 20 min at 4 °C and then with rabbit complement (Sigma-
Aldrich) for 30 min at 37 °C. Bone marrow myeloid precursors were cultured for
7 days in CM containing 50 ng/ml M-CSF (Immunotools, Friesoythe, Germany) or
10 ng/ml GM-CSF (R&D Systems, Abington, UK) to generate bone marrow-derived
Mφ (BMDM) and DCs (BMDCs), respectively. Non-adherent immature DCs were
purified at day 5 by positive selection using anti-CD11c mAb-coated magnetic
beads (Miltenyi Biotech). BMDM and BMDC populations contained 495% CD11b+
F4/80+ and CD11c+ I-Ab+ cells, respectively (data not shown).
Murine CD8+ and CD4+ T-cell purification: CD8+ T cells from OT1 mice
and CD4+ T cells from OT2 mice were isolated from the spleen and lymph nodes
using the CD8+ T-Cell Isolation Kit II and the CD4+ T-Cell Isolation Kit II, respectively,
following the manufacturer’s instructions (Miltenyi Biotech). Cell purity, determined
by staining for CD3, CD4, CD8, and CD11c expression, was 499% (data not
shown).
Induction of cell death. Spontaneous human neutrophil and murine
thymocyte apoptosis was induced by incubating cells in RPMI 1640 medium
containing 1% FCS. Staining with allophycocyanin (APC)-labeled Ann V (BD
Pharmingen, San Diego, CA, USA) and PI (Sigma-Aldrich) allowed to distinguish
four cell populations by flow cytometry, corresponding to viable (Ann V− PI−), early
apoptotic (Ann V+ PI−), late apoptotic (Ann V+ PI+) and secondary necrotic cells
(Ann V+/− PIhigh).32 In some experiments, cell necrosis was induced by incubating
cells at 56 °C for 30 min. Apoptosis of the human T-cell line Jurkat (ATCC,
Manassas, VA, USA) was induced by a 24-h incubation with 20 μg/ml etoposide
(Sigma-Aldrich) or 20 ng/ml anti-FAS mAb (clone CH-11; MBL International,
Woburn, MA, USA). Before each experiment, the Ann V/PI staining was assessed to
confirm cell apoptosis. In vivo apoptosis of cortical thymocytes was induced by
injecting mice intraperitoneally with 0.2 mg Dex (Calbiochem) per 25 g body
weight.22,44 After 24 h, the level of thymocyte apoptosis was evaluated by flow
cytometry, as described above.
Binding assays. Apoptotic or necrotic cells (1 × 105 cells/well) were resus-
pended in PBS containing 1% BSA (w/v) and incubated or not with 1 μM OG-labeled
human Clu, recombinant Clu (rClu), C1q, or HSA for 20 min at room temperature. The
binding of unlabeled Clu was detected with an anti-Clu mAb (Biotechne); mouse IgG1
antibody (R&D Systems) was used as a control. Bound antibodies were detected with
FITC-labeled anti-mouse Ig Ab (BD Pharmingen). Fluorescence was analyzed by flow
cytometry. In some experiments, apoptotic Jurkat T cells (containing at least 60%
Ann V+ PI+ cells) were treated for 1 h with 500 μg/ml DNase or for 30 min with
100 μg/ml pronase (both from Roche, Mannheim, Germany) or for 4 h with protein
deglycosylation mix (New England Biolabs) prior to the binding assay. In other
experiments, binding of Clu to 'flip-flopped' erythrocytes64 was measured. The binding
of Clu, SAP, CRP, and HSA to histone subunits and dsDNA was measured by a solid-
phase binding assay. Briefly, 1 μg/ml of each histone subunit was coated on 96-well
plates in 50 mM NaHCO3/Na2CO3 buffer, pH= 9.6, for 12 h at 4 °C. dsDNA was
coated as previously described.44 After blocking the nonspecific sites with PBS
containing 5% BSA, plates were incubated for 2 h with 1 μg/ml of biotinylated Clu,
SAP, CRP, and HSA and then with HRP-labeled streptavidin (Diaclone, Besançon,
France) diluted 1 : 500 for 1 h. The coating of dsDNA was verified using an
anti-dsDNA Ab (Immunotools) revealed by HRP-conjugated anti-mouse IgG Ab (Life
Technologies, Saint Aubin, France). Optical density was read at λ= 492 nm.
Phagocytosis assays
Phagocytosis assay with human cells: Freshly isolated neutrophils were
labeled with the green fluorescent dye PKH67 using the PKH67 Green Fluorescent
Cell Linker Kit (Sigma-Aldrich), according to the manufacturer’s instructions.
Apoptosis was induced as described above. Mφ (2 × 105 cells/well) were cultured in
48-well plates for 12 h before the assay. PKH67-labeled early (corresponding to a
cell population containing no late apoptotic cells) or late apoptotic neutrophils
(corresponding to a cell population containing at least 80% late apoptotic cells) were
incubated for 30 min in RPMI 1640 medium, containing or not 1 μM Clu, MBL, or
HSA. After washing, 1 × 106 neutrophils were added to Mφ and incubated for 40 min
at 37 °C in RPMI 1640 medium. Non-internalized apoptotic cells were removed by
washing Mφ with ice-cold PBS.32 Cells were then incubated with an APC-labeled
anti-HLA-DR mAb. Phagocytosis was analyzed by flow cytometry, as previously
described.32 In some experiments, apoptotic neutrophils were incubated for 30 min
in RPMI 1640 medium containing 30% human serum, depleted or not in Clu, prior to
the phagocytosis assay. Clu-depleted serums and control serums were prepared by
passing human serums over a column of anti-Clu mAb or isotype control mAb
covalently linked to agarose beads (co-IP columns; Pierce). Depletion was verified
by quantifying Clu by ELISA (Biotechne); results showed that 89± 2% (mean±
S.E.M., n= 4) of Clu was removed from the serum (not shown).
Phagocytosis assay with murine cells: Freshly isolated thymocytes from
C57BL/6 mice were labeled with PKH67, prior to apoptosis induction. BMDM
(2 × 105 cells/well) were cultured in 48-well plates for 12 h before the assay.
Opsonization of apoptotic thymocytes (80% late apoptotic cells) was performed as
described above. After washing with ice-cold PBS, BMDM were incubated with
phycoerythrin (PE)-labeled anti-F4/80 mAb. In some experiments, apoptotic
thymocytes were incubated with 1% (v:v) serum from WT or Clu− /− mice, prior
to incubation with BMDM. Results are expressed as a percentage of phagocytosis
(percentage of PKH67+ events among the HLA-DR+ or F4/80+ populations) or as a
phagocytic index determined as follows: (percentage of phagocytosis × MFI of
double-positive events)/100.63
Table 1 List of monoclonal antibodies (mAb) used
mAb Clone Reactivity Provider
Anti-B220 RA3-6B2 Mouse BD Pharmingen
Anti-CD19 MB19-1 Mouse eBioscience
Anti-CD3 145-2C11 Mouse eBioscience
Anti-CD4 L3T4 Mouse eBioscience
Anti-CD8 53-6.7 Mouse eBioscience
Anti-CD44 IM7 Mouse BD Pharmingen
Anti-CD11b M1/70 Mouse BD Pharmingen
Anti-CD11c N418 Mouse eBioscience
Anti-CD14 TUK4 Human Dako
Anti-CD19 MB19-1 Mouse eBioscience
Anti-CD45RA HI100 Mouse BD Pharmingen
Anti-CD62L MEL-14 Mouse eBioscience
Anti-Clu 350270 Human R&D Systems
Anti-dsDNA HpS22 Human/Mouse Immunotools
Anti-F4/80 BM8 Mouse Invitrogen
Anti-H2/H3/H4 HB-9 Human/Mouse AbD Serotec
Anti-H2-Kb AF6-88.5 Mouse BD Pharmingen
Anti-H4 F-9 Human/Mouse Santa Cruz Biotech




Anti-IFNγ 4S.B3 Mouse eBioscience
Anti-IL-2 JES6-5H4 Mouse eBioscience
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In vivo phagocytosis assay: Thymocytes from WT mice were labeled with
PKH67 and apoptosis was induced as described above. Apoptotic thymocytes
(1 × 108 cells containing at least 80% late apoptotic cells) were injected
intravenously into Clu− /− and WT mice. The frequencies of PKH67-labelled cells
among splenocytes were analyzed by flow cytometry 2 h after injection.
In vitro activation of OT1 and OT2 cells. Ova (Affiland, Liege, Belgium)
and BSA were first dialyzed and detoxified (EndoTrap system; Profos, Regensburg,
Germany) before use. Thymocytes from outbred Swiss mice were pulsed with 35 μM
Ova or BSA by osmotic shock, as previously described,50,65 prior to apoptosis induction.
Apoptotic thymocytes (containing at least 80% late apoptotic cells) were incubated or
not with albumin or murine rClu, in RPMI 1640 medium. After washing, 5 × 105
apoptotic thymocytes were co-cultured with 1 × 105 BMDCs and 1 × 105 OT1 or OT2
cells. After 24 h, the production of IL-2 was monitored by ELISA (BD Pharmingen).
Laser confocal scanning microscopy. Human Mφ were cultured on
glass slides in 48-well plates, 24 h prior to the phagocytosis assay. After
phagocytosis, Mφ were washed with ice-cold PBS, fixed in 2% (w/v)
paraformaldehyde (PFA) in PBS and stained with a PE-labeled anti-CD14 mAb.
Slides were then mounted with ProlonGold reagent (Invitrogen). In some
experiments, apoptotic neutrophils were incubated with OG-Clu as described
above and fixed with 2% PFA in PBS. In others, apoptotic neutrophils were stained
with anti-H2/H3/H4 mAb; bound mAb were detected with a PE-labeled anti-mouse
Ig Ab (Dako, Glostrup, Denmark). Cells were then mounted on glass slides with
ProlonGold reagent after nucleus staining with DAPI (Invitrogen). Staining was
analyzed with a confocal laser scanning system (A1Rsi, Nikon, Tokyo, Japan).
PCR analysis. The expression of the mRNA encoding SAP was analyzed in the
livers from Clu− /− and WT mice. Total RNA, purified using the RNeasy Plus MiniKit
(Qiagen, Düsseldorf, Germany) was reverse transcribed using the superscript
II Reverse Transcriptase (Invitrogen). mRNA expression was determined by reverse
transcriptase-PCR using iQ SYBR Green Supermix (Bio-Rad, Hercules, CA, USA).
Specific gene expression was calculated using the 2−ΔCT method (using GAPDH
as a calibrator).
Induction and monitoring of autoimmunity in mice. WTand Clu− /−
mice (8-week old) were injected intravenously with 1 × 107 irradiated apoptotic cells
(ATCC), once a week for 5 weeks (from week 1 to week 5). Serum samples were
collected once every 2 weeks after the first injection, for up to 10 weeks (at week 2,
4, 6, 8, and 10). Serum anti-dsDNA IgG Ab were quantified by ELISA (Alpha
Diagnostic International, San Antonio, TX, USA). Every 2 weeks, 4–6 mice from
each group were killed, and the kidneys, spleen, and lymph nodes were recovered.
Lymph node cells were stained with PE-Cy5-labeled anti-CD3, APCeFluor 780-
labeled anti-CD4 or anti-CD8 mAbs, FITC-labeled anti-CD19, PE-labeled anti-
CD44, and FITC-labeled anti-CD62L Abs. In some experiments, lymph node cells
were stimulated in vitro with 10 ng/ml PMA and 1 μM ionomycin for 6 h in the
presence of 10 μg/ml brefeldin A (all from Sigma-Aldrich). Cells were then fixed for
10 min with 4% PFA in PBS and incubated for 30 min in PBS containing 0.1% BSA
and 0.1% saponin (both from Sigma-Aldrich) with PeCy5-labeled anti-CD3,
FITC-labeled anti-CD4 mAb, APCeFluor 780-labeled anti-CD8, PE-labeled anti-IL-2,
and APC-labeled anti-IFNγ mAbs. Fluorescence was analyzed by flow cytometry.
Kidneys were frozen, cryosected, and fixed in cold acetone. Tissue sections were
stained with FITC-labeled goat anti-mouse IgG antibodies (Dako) or unlabeled rat
anti-C4 mAb (Cedarlane, Burlington, Canada). Binding of anti-C4 mAb was detected
with a FITC-labeled goat anti-rat Ig Ab (BD Biosciences, San Jose, CA, USA). After
washing, DAPI was added and the cells were mounted on glass slides with
ProlonGold reagent. Slides were examined using a Leica DMR fluorescence
microscope with an IM500 image manager system (Leica, Wetzlar, Germany).
Statistical analysis. Data are shown as mean±S.E.M. or as a percentage of
the increase ((B− A)/A) × 100) or decrease ((A−B)/A) × 100), where A is the
control value and B the value obtained with the protein of interest, mean±S.E.M.
Data were analyzed by the one-tailed Wilcoxon matched-pairs test or by the one-
tailed Mann–Whitney test or by two-way ANOVA test. P≤ 0.05 was considered
statistically significant.
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